1.Valenstein, M, Taylor, KK, Austin, K, Kales, HC, McCarthy, JF, Blow, FC. Benzodiazepine use among depressed patients treated in mental health settings. Am J Psychiatry. 2004;161:654–661.
2.Clark, RE, Xie, H, Brunette, MF. Benzodiazepine prescription practices and substance abuse in persons with severe mental illness. J Clin Psychiatry. 2004;65:151–155.
3.Brunette, MF, Noordsy, DL, Xie, H, Drake, RE. Benzodiazepine use and abuse among patients with severe mental illness and co-occurring substance use disorders. Psychiatr Serv. 2003;54:1395–1401.
4.Roeloffs, CA, Wells, KB, Ziedonis, D, Tang, L, Unutzer, J. Problem substance use among depressed patients in managed primary care. Psychosomatics. 2002;405–412.
5.Goodwin, GM. Neuropsychological and neuroimaging evidence for the involvement of the frontal lobes in depression. J Psychopharmacol. 1997;11:115–122.
6.Landry, MJ, Smith, DE, Steinberg, JR. Anxiety, depression, and substance use disorders: diagnosis, treatment, and prescribing practices. J Psychoactive Drugs. 1991;23:397–416.
7.Bingefors, K, Isacson, D, Von Knorring, L, Smedby, B, Ekselius, L, Kupper, LL. Antidepressant-treated patients in ambulatory care long-term use of non-psychotropic and psychotropic drugs. Br J Psychiatry. 1996;168:292–298.
8.Alonso, J, Angermeyer, MC, Bernert, S, et al.Psychotropic drug utilization in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatr Scand Suppl. 2004;420:55–64.
9.Rascati, K. Drug utilization review of concomitant use of specific serotonin reuptake inhibitors or clomipramine with antianxiety/sleep medications. Clin Ther. 1995;17:786–790.
10.Hales, RE, Hilty, DM, Brunson, GH. Cost savings with nefazodone in treating depression. J Clin Psychiatry. 2002;63(Suppl 1):48–51.
11.Fava, M, Rush, AJ, Trivedi, MH, et al.Background and rationale for the sequenced treatment alternatives to relieve depression (STAR*D) study. Psychiatr Clin North Am. 2003;26:457–494.
12.Rush, AJ, Fava, M, Wisniewski, SR, et al.Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. Control Clin Trials. 2004;25:119–142.
13.Hamilton, M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56–62.
14.Williams, JBW. A structured interview guide for the Hamilton Depression Rating Scale. Arch Gen Psychiatry. 1988;45:742–747.
15.Zimmerman, M, Mattia, JI. A self-report scale to help make psychiatric diagnoses: the Psychiatric Diagnostic Screening Questionnaire. Arch Gen Psychiatry. 2001;58:787–794.
16.Zimmerman, M, Mattia, JI. The Psychiatric Diagnostic Screening Questionnaire: development, reliability and validity. Compr Psychiatry. 2001;42:175–189.
17.Trivedi, MH, Rush, AJ, Ibrahim, HM, et al.The Inventory of Depressive Symptomatology, Clinician Rating (IDS-C) and Self-Report (IDS-SR), and the Quick Inventory of Depressive Symptomatology, Clinician Rating (QIDS-C) and Self-Report (QIDS-SR) in public sector patients with mood disorders: a psychometric evaluation. Psychol Med. 2004;34:73–82.
18.Rush, AJ, Trivedi, MH, Ibrahim, HM, et al.The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry. 2003;54:573–583.
19.Rush, AJ, Gullion, CM, Basco, MR, Jarrett, RB, Trivedi, MH. The Inventory of Depressive Symptomatology (IDS): psychometric properties. Psychol Med. 1996;26:477–486.
20.Rush, AJ, Bernstein, IH, Trivedi, MH, et al.An evaluation of the quick inventory of depressive symptomatology and the hamilton rating scale for depression: a sequenced treatment alternatives to relieve depression trial report. Biol Psychiatry. 2006;59:493–501.
21.Mundt, JC. Interactive voice response systems in clinical research and treatment. Psychiatr Serv. 1997;48:611–612.
22.Ware, J Jr., Kosinski, M, Keller, SD. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care. 1996;34:220–233.
23.Endicott, J, Nee, J, Harrison, W, Blumenthal, R. Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure. Psychopharmacol Bull. 1993;29:321–326.
24.Mundt, JC, Marks, IM, Shear, MK, Greist, JH. The Work and Social Adjustment Scale: a simple measure of impairment in functioning. Br J Psychiatry. 2002;180:461–464.
25.Reilly, MC, Zbrozek, AS, Dukes, EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics. 1993;4:353–365.
26.Wisniewski, SR, Rush, AJ, Balasubramani, GK, Trivedi, MH, Nierenberg, AA. Selfrated global measure of the frequency, intensity, and burden of side effects. J Psychiatr Pract. 2006;12:71–79.
27.Trivedi, MH, Rush, AJ, Wisniewski, SR, et al.Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006;163:28–40.
28.Rush, AJ, Trivedi, MH, Wisniewski, SR, et al.Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med. 2006;354:1231–1242.
29.Trivedi, MH, Fava, M, Wisniewski, SR, et al.Medication augmentation after the failure of SSRIs for depression. N Engl J Med. 2006;354:1243–1252.
30.Kendler, KS, Heath, AC, Neale, MC, Kessler, RC, Eaves, LJ. Alcoholism and major depression in women. A twin study of the causes of comorbidity. Arch Gen Psychiatry. 1993;50:690–698.
31.Swendsen, JD, Merikangas, KR, Canino, GJ, Kessler, RC, Rubio-Stipec, M, Angst, J. The comorbidity of alcoholism with anxiety and depressive disorders in four geographic communities. Compr Psychiatry. 1998;39:176–184.
32.Grant, BF. Comorbidity between DSM-IV drug use disorders and major depression: results of a national survey of adults. J Subst Abuse. 1995;7:481–497.